2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
Gross Profit
2Seventy Bio Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
2Seventy Bio Inc
NASDAQ:TSVT
|
Gross Profit
$83.5m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is 2Seventy Bio Inc's Gross Profit?
Gross Profit
83.5m
USD
Based on the financial report for Dec 31, 2023, 2Seventy Bio Inc's Gross Profit amounts to 83.5m USD.
What is 2Seventy Bio Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
9%
Over the last year, the Gross Profit growth was 11%. The average annual Gross Profit growth rates for 2Seventy Bio Inc have been -30% over the past three years , 9% over the past five years .